Pre-made Ranibizumab benchmark antibody ( Fab, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-470

Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-470-1mg 1mg 3090
GMP-Bios-ab-470-10mg 10mg Inquiry
GMP-Bios-ab-470-100mg 100mg Inquiry
GMP-Bios-ab-470-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody
INN Name Ranibizumab
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure1cz8:HL:YX
99% SI StructureNone
95-98% SI Structure1bj1:HL:KJ/6bft:HL:AB
Year Proposed2004
Year Recommended2004
CompaniesGenentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn
Conditions ApprovedChoroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy
Conditions ActiveRetinopathy of prematurity;Polypoidal choroidal vasculopathy
Conditions DiscontinuedRetinal telangiectasis
Development Techna